A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.

VDKPPYLPRPRPIRrPGGr

Identity summarySpecific molecular form represented

Identity status: Specific molecular form represented
Residues: 19
Peptidoform features: 2
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0036499	—	—	—	Notation only	4

Residue view

Residue display

19 residues

V1D2K3P4P5Y6L7P8R9P10R11P12I13R14R15P16G17G18R19

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

Reported residue markerpos 15

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported residue markerpos 19

Lowercase residue token

A lowercase one-letter residue was reported. It is shown as the parent residue here and kept as a reported marker until stereochemistry or modification can be normalized.

Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

VDKPPYLPRPRPIRRPGGR

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached

3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors19 aa · pI 12.3 · GRAVY -1.53

Length: 19 aa
Monoisotopic mass: 2226.30 Da
Average mass: 2227.65 Da
Net charge at pH 7.4: 5.00
Estimated pI: 12.34
GRAVY: -1.532
KD-positive residues: 15.8%
Aromatic residues: 5.3%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophilic
Amphipathic moment (μH): 0.28
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

6.96

pH 5

5.11

pH 6

5.01

pH 7.4

4.94

pH 9

4.19

pH 12

0.87

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Acidic (D,E)

1 · 5.3%

Basic (K,R,H)

6 · 31.6%

Hydrophobic aliphatic (A,V,I,L,M)

3 · 15.8%

Aromatic (F,W,Y)

1 · 5.3%

Conformational / sulfur (G,P,C)

8 · 42.1%

Top residues

P631.6%R526.3%G210.5%D15.3%I15.3%L15.3%K15.3%Y15.3%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

1-7

VDKPPYL

GRAVY -0.557

Most hydrophilic window

9-15

RPRPIRR

GRAVY -2.386

13 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

8-19

PRPRPIRRPGGR

μH 1.10 · charge 5.0

15 aa window

5-19

PYLPRPRPIRRPGGR

μH 0.84 · charge 5.0

12 aa window

4-15

PPYLPRPRPIRR

μH 0.84 · charge 4.0

12 aa window

7-18

LPRPRPIRRPGG

μH 0.76 · charge 4.0

12 aa window

5-16

PYLPRPRPIRRP

μH 0.73 · charge 4.0

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Pro/Gly-rich sequence

P/G · pos 4, 5, 8, 10, 12, 16 +2

High Pro/Gly content can affect local flexibility and secondary-structure propensity.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 0.28100°/residue · 19 aa

Hydrophobic moment0.28

Mean K-D hydropathy-1.53

Approx. net charge+5

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

56.32

Instability index

72.5

Above 40 — predicted unstable in vitro.

Boman index

3.85 kcal/mol

Above 2.48 — elevated potential protein-binding.

Molar extinction coefficient (280 nm)

1,490 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 0.67

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Metabolic & Proteolytic Stability

2 records

How stable is the peptide in biological matrices or protease systems?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeSerum/plasma stability

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Serum/plasma stability2 records · 2 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	71.10 ± 3.43 Minutes 4266 seconds	Eligible when experimental context matches	HPLC · rat · Wistar rats blood plasma	Result: Reported point value · Molecular form: ATLPF0036499 · Dose/window: 31.5 μmol/L · Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 175 and 270min · Wistar rats blood plasma protease · In Vitro · Source: Primary reference linked	Reference
2	242.44 ± 39.21 Minutes 14546.4 seconds	Eligible when experimental context matches	HPLC · rat · Wistar rats blood plasma	Result: Reported point value · Molecular form: ATLPF0036499 · Dose/window: 31.5 μmol/L · Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 270, 300, 400, 600 and... · Wistar rats blood plasma protease · In Vitro · Source: Primary reference linked	Reference

Excretion / Persistence

2 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life2 records · 0 matched-context · 2 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	97.91999999999999 seconds	Interpret as reported	rat · Wistar rats blood sample	Result: Reported point value · Molecular form: ATLPF0036499 · Route: IV · Dose/window: 1 mg/ml · Wistar rats blood protease · In Vivo · Source: Primary reference linked	Reference
2	1685.4 seconds	Interpret as reported	rat · Wistar rats blood sample	Result: Reported point value · Molecular form: ATLPF0036499 · Route: IV · Dose/window: 1 mg/ml · Wistar rats blood protease · In Vivo · Source: Primary reference linked	Reference

Toxicity / Safety

4 records

What safety, toxicity, or tolerability evidence is attached?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scope% hemolysis

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

% hemolysis4 records · 4 matched-context · 0 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	0 %	Eligible when experimental context matches	Human erythrocytes · Human erythrocytes · human · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Source record
2	5 %	Eligible when experimental context matches	Rabbit erythrocytes · Rabbit erythrocytes · rabbit · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
3	8 %	Eligible when experimental context matches	Rabbit erythrocytes · Rabbit erythrocytes · rabbit · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference
4	10 %	Eligible when experimental context matches	Rabbit erythrocytes · Rabbit erythrocytes · rabbit · RBC	Result: Reported point value · Molecular form: not reported · Source: Primary reference linked	Reference

Evidence landscape

8 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

0 evidence records

Metabolic & Proteolytic Stability

2 evidence records

Excretion / Persistence

2 evidence records

Toxicity / Safety

4 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Hemolysis Percent Observation

Half Life

Serum Plasma Stability

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Cell / safety model

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrix

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Toxicity / Safety Safety	Hemolysis Percent Observation	5 %	Reported point value	Eligible when experimental context matches	Rabbit erythrocytes · rabbit · RBC	Not specified	Reference Primary reference linked
2	Toxicity / Safety Safety	Hemolysis Percent Observation	8 %	Reported point value	Eligible when experimental context matches	Rabbit erythrocytes · rabbit · RBC	Not specified	Reference Primary reference linked
3	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	71.10 ± 3.43 Minutes 4,266 seconds	Reported point value	Eligible when experimental context matches	HPLC · rat · Wistar rats blood plasma	Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 175 and 270min · Dose/window: 31.5 μmol/L · Protease: Wistar rats blood plasma protease · In Vitro	Reference Primary reference linked
4	Toxicity / Safety Safety	Hemolysis Percent Observation	10 %	Reported point value	Eligible when experimental context matches	Rabbit erythrocytes · rabbit · RBC	Not specified	Reference Primary reference linked
5	Excretion / Persistence Persistence	Half Life	97.92 seconds	Reported point value	Interpret as reported	rat · Wistar rats blood sample	Route: IV · Dose/window: 1 mg/ml · Protease: Wistar rats blood protease · In Vivo	Reference Primary reference linked
6	Excretion / Persistence Persistence	Half Life	1,685.4 seconds	Reported point value	Interpret as reported	rat · Wistar rats blood sample	Route: IV · Dose/window: 1 mg/ml · Protease: Wistar rats blood protease · In Vivo	Reference Primary reference linked
7	Metabolic & Proteolytic Stability Stability	Serum Plasma Stability	242.44 ± 39.21 Minutes 14,546.4 seconds	Reported point value	Eligible when experimental context matches	HPLC · rat · Wistar rats blood plasma	Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 270, 300, 400, 600 and 1000min · Dose/window: 31.5 μmol/L · Protease: Wistar rats blood plasma pr...	Reference Primary reference linked
8	Toxicity / Safety Safety	Hemolysis Percent Observation	0 %	Reported point value	Eligible when experimental context matches	Human erythrocytes · human · RBC	Not specified	Source record Primary reference linked

1–8 / 8

Identity & reference map

8 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary2 reference groups

Identity type: canonical sequence
Reported notation: 0
Reference groups: 2
Measurements: 8
ATL peptide ID: ATLPC0033580

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 8

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 8

Different notation

Reported notation does not resolve to the current display sequence.

0 / 8

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

8 / 8

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

VDKPPYLPRPRPIRrPGGr

Reported names

No distinct human-readable aliases are exposed.

Reference map2 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	PersistenceSafetyStability Half Life, Hemolysis Percent Observation, Serum Plasma Stability	No reported alias	7 identity 7 evidence
Source record Open	Safety Hemolysis Percent Observation	No reported alias	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0033580
Identity type: canonical sequence
ADMET endpoints: 3
Evidence records: 8
Reference groups: 2
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0033580

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0033580' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0036499

—

Notation only

Value

Analysis use

Assay / model

Result context

Reference

71.10 ± 3.43 Minutes

4266 seconds

Eligible when experimental context matches

HPLC · rat · Wistar rats blood plasma

Result: Reported point value · Molecular form: ATLPF0036499 · Dose/window: 31.5 μmol/L · Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 175 and 270min · Wistar rats blood plasma protease · In Vitro · Source: Primary reference linked

Reference

242.44 ± 39.21 Minutes

14546.4 seconds

Eligible when experimental context matches

HPLC · rat · Wistar rats blood plasma

Result: Reported point value · Molecular form: ATLPF0036499 · Dose/window: 31.5 μmol/L · Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 270, 300, 400, 600 and... · Wistar rats blood plasma protease · In Vitro · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

97.91999999999999 seconds

Interpret as reported

rat · Wistar rats blood sample

Result: Reported point value · Molecular form: ATLPF0036499 · Route: IV · Dose/window: 1 mg/ml · Wistar rats blood protease · In Vivo · Source: Primary reference linked

Reference

1685.4 seconds

Interpret as reported

rat · Wistar rats blood sample

Result: Reported point value · Molecular form: ATLPF0036499 · Route: IV · Dose/window: 1 mg/ml · Wistar rats blood protease · In Vivo · Source: Primary reference linked

Reference

Value

Analysis use

Assay / model

Result context

Reference

0 %

Eligible when experimental context matches

Human erythrocytes · Human erythrocytes · human · RBC

Result: Reported point value · Molecular form: not reported · Source: Primary reference linked

Source record

5 %

Eligible when experimental context matches

Rabbit erythrocytes · Rabbit erythrocytes · rabbit · RBC

Result: Reported point value · Molecular form: not reported · Source: Primary reference linked

Reference

8 %

Eligible when experimental context matches

Rabbit erythrocytes · Rabbit erythrocytes · rabbit · RBC

Result: Reported point value · Molecular form: not reported · Source: Primary reference linked

Reference

10 %

Eligible when experimental context matches

Rabbit erythrocytes · Rabbit erythrocytes · rabbit · RBC

Result: Reported point value · Molecular form: not reported · Source: Primary reference linked

Reference

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Toxicity / Safety

Safety

Hemolysis Percent Observation

5 %

Reported point value

Eligible when experimental context matches

Rabbit erythrocytes · rabbit · RBC

Not specified

Reference

Primary reference linked

Toxicity / Safety

Safety

Hemolysis Percent Observation

8 %

Reported point value

Eligible when experimental context matches

Rabbit erythrocytes · rabbit · RBC

Not specified

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

71.10 ± 3.43 Minutes

4,266 seconds

Reported point value

Eligible when experimental context matches

HPLC · rat · Wistar rats blood plasma

Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 175 and 270min · Dose/window: 31.5 μmol/L · Protease: Wistar rats blood plasma protease · In Vitro

Reference

Primary reference linked

Toxicity / Safety

Safety

Hemolysis Percent Observation

10 %

Reported point value

Eligible when experimental context matches

Rabbit erythrocytes · rabbit · RBC

Not specified

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

97.92 seconds

Reported point value

Interpret as reported

rat · Wistar rats blood sample

Route: IV · Dose/window: 1 mg/ml · Protease: Wistar rats blood protease · In Vivo

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

1,685.4 seconds

Reported point value

Interpret as reported

rat · Wistar rats blood sample

Route: IV · Dose/window: 1 mg/ml · Protease: Wistar rats blood protease · In Vivo

Reference

Primary reference linked

Metabolic & Proteolytic Stability

Stability

Serum Plasma Stability

242.44 ± 39.21 Minutes

14,546.4 seconds

Reported point value

Eligible when experimental context matches

HPLC · rat · Wistar rats blood plasma

Time: Aliquots were analyzed after 0, 20, 30, 40, 60, 80, 90, 100, 120, 150, 180, 210, 240, 270, 300, 400, 600 and 1000min · Dose/window: 31.5 μmol/L · Protease: Wistar rats blood plasma pr...

Reference

Primary reference linked

Toxicity / Safety

Safety

Hemolysis Percent Observation

0 %

Reported point value

Eligible when experimental context matches

Human erythrocytes · human · RBC

Not specified

Source record

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

PersistenceSafetyStability

Half Life, Hemolysis Percent Observation, Serum Plasma Stability

No reported alias

7 identity

7 evidence

Source record

Open

Safety

Hemolysis Percent Observation

No reported alias

1 identity

1 evidence

ATLPC0033580

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Metabolic & Proteolytic Stability

Excretion / Persistence

Toxicity / Safety

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue

ATLPC0033580

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Metabolic & Proteolytic Stability

Excretion / Persistence

Toxicity / Safety

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue